Notably, CD86+ CLL cells were predictive for time to treatment in both IgV-Mut as well as in IgV-UM cases, which corroborates our data from targeted VDJ/Sμ resequencing, showing that AID is active in IgV-Mut as well as IgV-UM samples. The gene discussed is CD86; the disease is B-cell chronic lymphocytic leukemia.